aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update.
- Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments.
- SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update.
- Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
- G&A Expenses: General and administrative expenses were $3.5 million for the first quarter 2024.